Daptomycin oral - Merck

Drug Profile

Daptomycin oral - Merck

Alternative Names: Oral daptomycin - Merck; Oral daptomycin analogues - Merck/Emisphere

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Cubist Pharmaceuticals
  • Class Antibacterials; Cyclic peptides; Lipopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 20 Sep 2004 Discontinued - Preclinical for Bacterial infections in USA (PO)
  • 31 Dec 2002 Suspended - Preclinical for Bacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top